Document series
Trial abstracts — page 9
700 structured trial abstracts. Each is one document in five parts: abstract, design and population, results, certainty assessment and citing documents.
Showing 0 records on this page
Trial records
700 documents · page 9 of 30
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| SURPASS-CVOT-DDIprogramme record | Tirzepatide | Phase 1 | Reported | Randomised crossover | — | 2025 | Very low |
| SURPASS-CVOT-PKprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| SURPASS-CVOT-RENAL-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| DREAMS-2-PKprogramme record | Mazdutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| DREAMS-2-RENAL-IMPprogramme record | Mazdutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| FLOW-HEPATIC-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| FLOW-PKprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| FLOW-RENAL-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| MARITIDE-PH2-OBESITY-HEPATIC-IMPprogramme record | Maridebart cafraglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| MARITIDE-PH2-T2D-BODY-COMPprogramme record | Maridebart cafraglutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| MARITIDE-PH2-T2D-REGIONAL-CNprogramme record | Maridebart cafraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| MARITIDE-PH2-T2D-REGIONAL-JPprogramme record | Maridebart cafraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| PETRE-PH1B-ADHERENCEprogramme record | Petrelintide | Phase 1 | Reported | Observational | — | 2024 | Very low |
| PETRE-PH1B-BIOMARKERprogramme record | Petrelintide | Phase 1 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| PETRE-PH1B-ELDERLYprogramme record | Petrelintide | Phase 1 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| PETRE-PH1B-PKprogramme record | Petrelintide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| REIMAGINE-1-DDIprogramme record | Amycretin | Phase 1 | Reported | Randomised crossover | — | 2024 | Very low |
| REIMAGINE-1-PKprogramme record | Amycretin | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| REIMAGINE-1-RENAL-IMPprogramme record | Amycretin | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| STEP-HFpEF-DM-BODY-COMPprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SUMMIT-ADHERENCEprogramme record | Tirzepatide | Phase 3 | Reported | Observational | — | 2024 | Very low |
| SUMMIT-BIOMARKERprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SUMMIT-ELDERLYprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SUMMIT-OLEprogramme record | Tirzepatide | Phase 3 | Reported | Single-arm open-label | — | 2024 | Very low |
page 9 of 30